Are we there yet? CAR‐T therapy in multiple myeloma
Eitan Mirvis, Reuben Benjamin · 2024
Read Are we there yet? CAR‐T therapy in multiple myeloma by Eitan Mirvis, Reuben Benjamin (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11637742.txt.
Description
Eitan Mirvis and Reuben Benjamin reviewed cell therapy for multiple myeloma in twenty twenty-four, asking how close it comes to a cure. The therapy trains a patient's own T cells to hunt a marker on myeloma cells, and it won approval in the United States and Europe in twenty twenty-one. Response rates in heavily pre-treated patients were striking, yet relapse stays common.
Making the cells is slow and costly, and past myeloma treatment leaves T cells worn. The review weighs next steps: sharper engineered cells, off-the-shelf cells from donors, and fresh targets beyond the main marker. It also covers paths by which myeloma resists the therapy. The authors map the hurdles still ahead on the road to a lasting cure and judge what each new approach must prove.
Catalog record
| CREATOR | Eitan Mirvis, Reuben Benjamin |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 62 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |